上游生物加工市场 - 按产品、使用方式、方式、应用、最终用户 - 全球预测，2024 年 - 2032 年

上游生物加工市场规模预计从 2024 年到 2032 年将以 9.7% 的复合年增长率扩大。随着对有效治疗的需求不断增加，慢性病的盛行率不断上升，从而促进了生物製剂的生产，并为生物加工技术的更广泛采用铺平了道路。

政府对生物技术研发的有利倡议和投资的涌入正在推动上游生物加工产业的创新。举个例子，2023年9月，Sartorius和Repligen公司推出了整合式生物反应器系统，将前者的Biostat搅拌槽反应器（STR）与Repligen的XCell交替切向流（ATF）技术结合。

製药公司合约製造组织 (CMO) 的扩张和生物加工活动的外包也增加了上游生物加工的采用。此外，细胞培养技术和一次性生物反应器的技术创新正在提高效率和可扩展性，进一步推动产业成长。

上游生物加工市场分为产品、使用方式、方式、应用、最终用户和地区。

在产品方面，预计2024年至2032年间细胞培养产品领域的市场价值将以12.5%的增长率增长。细胞培养技术的重大进步（例如一次性生物反应器）正在提高效率和可扩展性。生物技术和製药行业的扩张也将增加对细胞培养产品的需求。

在应用方面，到2032年，疫苗生产领域的上游生物加工产业将以复合年增长率10.8%的速度扩张。生物技术的进步正在促进新型候选疫苗的开发，并增加了对上游生物加工技术的吸引力。政府为疫苗研发提供资金将进一步有利于该领域的成长。

从地区来看，由于政府和私人组织对生技研发的投资不断增加，亚太地区上游生物加工市场在2024年至2032年期间的复合年增长率将达到12.1%。慢性病的日益普及刺激了对生物製药的需求，并推动了对上游生物加工解决方案的需求。大量熟练劳动力的存在和较低的製造成本正在吸引生物技术公司，进一步推动区域产业的发展。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 越来越多地采用一次性生物处理系统
    • 过程分析技术 (PAT) 的实施不断增加
    • 对生物製药的需求不断增加
  • 产业陷阱与挑战
    • 资金成本高
    • 与上游生物加工相关的技术和营运挑战
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

• 主要趋势
• 生物反应器/发酵罐
• 细胞培养产品
• 过滤器
• 生物反应器配件
• 袋子和容器
• 其他产品

第 6 章：市场估计与预测：按使用模式，2018 年 - 2032 年

• 主要趋势
• 多用途
• 一次使用

第 7 章：市场估计与预测：按模式，2018 - 2032

• 主要趋势
• 内部
• 外包

第 8 章：市场估计与预测：按应用划分，2018 年 - 2032 年

• 主要趋势
• 单株抗体生产
• 疫苗生产
• 细胞和基因治疗生产
• 其他应用

第 9 章：市场估计与预测：按最终用户划分，2018 年 - 2032 年

• 主要趋势
• 生物製药公司
• CDMO 和 CRO
• 研究和学术机构

第 10 章：市场估计与预测：按地区，2018 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 11 章：公司简介

• Applikon Biotechnology
• Boehringer Ingelheim GmbH
• CellGenix GmbH
• Corning, Inc.
• Danaher Corporation (Cytvia)
• Eppendorf AG
• Merck KGaA
• PBS Biotech, Inc.
• Sartorius AG
• Thermo Fisher Scientific Inc.

Upstream Bioprocessing Market size is projected to expand at 9.7% CAGR from 2024 to 2032. Rapid advancements in biotechnology and genetic engineering are driving the development of novel biopharmaceuticals, subsequently accelerating the demand for upstream bioprocessing solutions. The growing prevalence of chronic diseases along the rising need for effective treatments is boosting the production of biologics and making way for the higher adoption of bioprocessing technologies.

The influx of favorable government initiatives and investments in biotechnology R&D is driving innovations in the upstream bioprocessing industry. To cite an instance, in September 2023, Sartorius and Repligen Corporation introduced an integrated bioreactor system, combining the former's Biostat Stirred-Tank Reactor (STR) with Repligen's XCell Alternating Tangential Flow (ATF) technology.

The expansion of contract manufacturing organizations (CMOs) and outsourcing of bioprocessing activities by pharmaceutical companies is also increasing the adoption of upstream bioprocessing. Moreover, technological innovations in cell culture techniques and single-use bioreactors are leading to enhanced efficiency and scalability, further driving the industry growth.

The upstream bioprocessing market is segregated into product, usage mode, mode, application, end-user, and region.

In terms of product, the market value from the cell culture products segment is anticipated to rise at 12.5% growth rate between 2024 and 2032. The increasing demand for biopharmaceuticals is fueling the need for cell culture products for protein expression and production. Significant advancements in cell culture techniques, like single-use bioreactors are improving efficiency and scalability. The expansion of biotechnology and pharmaceutical sector will also boost the demand for cell culture products.

With respect to application, the upstream bioprocessing industry from the vaccine production segment will expand at 10.8% CAGR until 2032. The rising global demand for vaccines to combat infectious diseases is driving the need for efficient bioprocessing solutions. The advancements in biotechnology are facilitating the development of novel vaccine candidates and increasing the appeal for upstream bioprocessing technologies. The rollout of government funding for vaccine R&D will further benefit the segment growth.

Regionally, the Asia Pacific upstream bioprocessing market will record 12.1% CAGR between 2024 and 2032, on account of the increasing investments in biotechnology R&D by government and private organizations. The growing prevalence of chronic diseases is fueling the demand for biopharmaceuticals and driving the need for upstream bioprocessing solutions. The presence of a large pool of skilled labor and lower manufacturing costs are attracting biotechnology companies, further driving the regional industry progression.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing adoption of single-use bioprocessing systems
    • 3.2.1.2 Rising implementation of process analytical technology (PAT)
    • 3.2.1.3 Increasing demand for biopharmaceuticals
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High capital costs
    • 3.2.2.2 Technical and operational challenges related to upstream bioprocessing
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Bioreactors/Fermenters
• 5.3 Cell culture products
• 5.4 Filters
• 5.5 Bioreactor accessories
• 5.6 Bags & containers
• 5.7 Other products

Chapter 6 Market Estimates and Forecast, By Usage Mode, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Multi-use
• 6.3 Single-use

Chapter 7 Market Estimates and Forecast, By Mode, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 In-house
• 7.3 Outsourced

Chapter 8 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Monoclonal antibody production
• 8.3 Vaccine production
• 8.4 Cell and gene therapy production
• 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Biopharmaceutical companies
• 9.3 CDMOs and CROs
• 9.4 Research and academic institutes

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Applikon Biotechnology
• 11.2 Boehringer Ingelheim GmbH
• 11.3 CellGenix GmbH
• 11.4 Corning, Inc.
• 11.5 Danaher Corporation (Cytvia)
• 11.6 Eppendorf AG
• 11.7 Merck KGaA
• 11.8 PBS Biotech, Inc.
• 11.9 Sartorius AG
• 11.10 Thermo Fisher Scientific Inc.